Total amount raised
$693 Millions
Latest funding date
Location
Generate Biomedicines has successfully raised funds through multiple rounds, with notable investors including Samsung Life Science Fund and Alumni Ventures. The company leverages machine learning and biological engineering to develop innovative biomedicines.
Keep reading to explore the intricacies of Generate Biomedicines' fundraising journey and the investors backing this pioneering platform.
What Is Generate Biomedicines?
Generate Biomedicines, founded in 2018, is a biotech company based in Somerville, Massachusetts. The company was established by Geoffrey von Maltzahn, Gevorg Grigoryan, Molly Gibson, Noubar Afeyan, and Sophie de Boer.
Specializing in generative biology, Generate Biomedicines leverages machine learning and biological engineering to create breakthrough medicines. Their innovative platform accelerates the drug discovery process by generating new biological molecules with therapeutic value.
With a team of 251-500 employees, Generate Biomedicines continues to push the boundaries of medicine, aiming to revolutionize the way new drugs are developed and brought to market.
How Much Funding Has Generate Biomedicines Raised?
- Series A
- Amount Raised: $50M
- Date: September 2020
- Lead Investors: Flagship Pioneering
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the initial development and scaling of their generative biology platform.
- Series B
- Amount Raised: $370M
- Date: November 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To move antibodies to clinical trial stages and prepare for additional clinical trials.
- Series C
- Amount Raised: $273M
- Date: September 2023
- Lead Investors: Alumni Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To bring other drug programs into clinical and preclinical testing stages, file applications with the FDA, and initiate multiple clinical trials annually.
- Venture Round
- Amount Raised: Not disclosed
- Date: December 2024
- Lead Investors: Samsung Life Science Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further expand their drug discovery and development capabilities.
Total Amount Raised: $693M
Current Valuation: Not publicly disclosed
Key Investors
- Samsung Life Science Fund
- Details: Samsung Life Science Fund is an investment fund focused on the life sciences sector. They aim to support companies that are innovating in biotechnology and pharmaceuticals.
- Investment Focus Areas: Biotechnology, pharmaceuticals, life sciences.
- Notable Investments: Generate Biomedicines.
- Alumni Ventures
- Details: Alumni Ventures is a venture capital firm that provides accredited investors with access to venture capital. They invest in a wide range of industries, supporting innovative startups.
- Investment Focus Areas: Technology, healthcare, consumer products.
- Notable Investments: Generate Biomedicines.
- Flagship Pioneering
- Details: Flagship Pioneering is a venture capital firm that creates and funds early-stage life sciences companies. They are known for launching and supporting groundbreaking biotech firms.
- Investment Focus Areas: Biotechnology, life sciences, healthcare.
- Notable Investments: Moderna, Seres Therapeutics, Rubius Therapeutics.
- Abu Dhabi Investment Authority (ADIA)
- Details: ADIA is a sovereign wealth fund owned by the Emirate of Abu Dhabi. They manage a diversified global investment portfolio.
- Investment Focus Areas: Equities, fixed income, real estate, private equity, infrastructure.
- Notable Investments: Various global investments across multiple sectors.
- Fidelity Management & Research Company
- Details: Fidelity is an American multinational financial services corporation. They offer a wide range of financial products and services.
- Investment Focus Areas: Mutual funds, ETFs, retirement services, wealth management, life insurance.
- Notable Investments: Various investments across technology, healthcare, consumer sectors.
What's Next for Generate Biomedicines?
Generate Biomedicines stands at the cusp of significant opportunities, driven by its AI-powered drug discovery platform. With nearly $700 million raised, the company is poised to advance its pipeline of 17 programs, including collaborations with Amgen and MD Anderson Cancer Center. These partnerships could yield substantial returns, potentially worth billions.
Future fundraising efforts are likely to attract new investors, given the company's robust progress and strategic collaborations. However, challenges such as economic uncertainty and the high costs of clinical trials loom large. Navigating regulatory hurdles and demonstrating clinical efficacy will be crucial for sustained growth.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Generate Biomedicines and gather other critical business insights. Sign up for free and unlock the potential of data-driven decision-making today.
